Higher price of Covaxin in private markets needed to sustain costs: Bharat Biotech

Supply to the government of India at ₹150 per dose is a non-competitive price and clearly not sustainable in the long run, the company said

Comments

Popular posts from this blog

Congress groomed me not to sit at home: Shivakumar

Infosys lays off hundreds after failing internal assessments in Mysuru

Greater Bengaluru Committee proposes seven municipal corporations